Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07122986 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
A Phase 1 study of Healthy Participants, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 310
- Enrollment target
- 11
- Study locations
NCT07122986 is a Phase 1 study of Healthy Participants that is actively recruiting participants, run by Pfizer. The registered enrollment target is 310 participants, above the 63-participant average among 119 other Healthy Participants trials with a reported enrollment target (392% higher). The trial reports 11 study locations across 5 states.
The verdict
NCT07122986, a Phase 1 study of Healthy Participants, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 310 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study evaluates an investigational vaccine designed to protect against Escherichia coli (E coli). The primary objective is to assess the safety and tolerability of E coli vaccines administered intramuscularly to healthy adults.
Conditions Studied
Interventions
- DRUG E coli vaccine 1 Dose A
- DRUG E coli vaccine 1 Dose B
- DRUG E coli vaccine 2
- DRUG E coli vaccine 3
- DRUG E coli Vaccine 4 Dose A
Study Locations (11)
California
- Anaheim Clinical Trials, LLC - Anaheim
- Orange County Research Center - Lake Forest
- Diablo Clinical Research, Inc. - Walnut Creek
Tennessee
- Alliance for Multispecialty Research, LLC - Knoxville
- Alliance for Multispecialty Research, LLC - Knoxville
- University Eye Specialists, P.C. (Ophthalmologist) - Maryville
Florida
- Miami Eye Institute - Hollywood
- Research Centers of America - Hollywood
Ohio
- CTI Clinical Research Center - Cincinnati
- Senders Pediatrics - South Euclid
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2025-08-11 |
| Est. Completion | 2028-05-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07122986
The ClinicalTrials.gov registry entry for NCT07122986 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 63-participant average among 119 other Healthy Participants trials with a reported enrollment target (392% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 5 interventions - of which E coli vaccine 1 Dose A is the first listed.
NCT07122986 reports 11 study locations spanning 5 distinct geographic areas - top geographies include California, Tennessee, Florida.
Frequently Asked Questions
What is clinical trial NCT07122986 about?
NCT07122986 is a clinical study titled "A Study to Learn About a Vaccine Against E Coli in Healthy Adults". This study evaluates an investigational vaccine designed to protect against Escherichia coli (E coli). The primary objective is to assess the safety and tolerability of E coli vaccines administered intramuscularly to healthy adults.
What is the current status of trial NCT07122986?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 310 participants. The study started on 2025-08-11. Estimated completion is 2028-05-26.
What conditions does trial NCT07122986 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT07122986?
The interventions under investigation include: E coli vaccine 1 Dose A (DRUG), E coli vaccine 1 Dose B (DRUG), E coli vaccine 2 (DRUG), E coli vaccine 3 (DRUG), E coli Vaccine 4 Dose A (DRUG).
Who is sponsoring clinical trial NCT07122986?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07122986 being conducted?
This trial has 11 study locations across California, Florida, New York, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.